About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: TCON
- Previous Close: $3.90
- 50 Day Moving Average: $4.69
- 200 Day Moving Average: $5.55
- 52-Week Range: $3.60 - $7.90
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.73
- P/E Growth: 0.00
- Market Cap: $50.95M
- Outstanding Shares: 13,065,000
- Beta: 2.77
- Net Margins: -750.91%
- Return on Equity: -137.76%
- Return on Assets: -72.55%
Companies Related to TRACON Pharmaceuticals:
- Debt-to-Equity Ratio: 0.27%
- Current Ratio: 2.77%
- Quick Ratio: 2.77%
What is TRACON Pharmaceuticals' stock symbol?
TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."
Where is TRACON Pharmaceuticals' stock going? Where will TRACON Pharmaceuticals' stock price be in 2017?
4 brokerages have issued 1-year price objectives for TRACON Pharmaceuticals' shares. Their predictions range from $10.00 to $15.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $13.00 in the next twelve months.
When will TRACON Pharmaceuticals announce their earnings?
TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
Who owns TRACON Pharmaceuticals stock?
TRACON Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (6.66%), Eventide Asset Management LLC (6.62%), Wall Street Associates (1.85%), Perceptive Advisors LLC (0.77%), Alyeska Investment Group L.P. (0.77%) and Renaissance Technologies LLC (0.31%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, H Casey Logan, Jafco Super V3 Investment Limi, Peter W Sonsini and Ronald L Shazer.
Who sold TRACON Pharmaceuticals stock? Who is selling TRACON Pharmaceuticals stock?
TRACON Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sii Investments Inc. WI.
Who bought TRACON Pharmaceuticals stock? Who is buying TRACON Pharmaceuticals stock?
TRACON Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Eventide Asset Management LLC, Perceptive Advisors LLC, Alyeska Investment Group L.P. and Renaissance Technologies LLC.
How do I buy TRACON Pharmaceuticals stock?
Shares of TRACON Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of TRACON Pharmaceuticals stock cost?
One share of TRACON Pharmaceuticals stock can currently be purchased for approximately $3.90.